Navigation Links
Surrogate markers


A surrogate marker (or surrogate end point) is term used in medical research for a change to the human body that is believe to be necessary to an eventual outcome or end point.[1]

Surrogate markers are used when it is unethical to look for the end point (e.g., death) in the experiment, or when the number of end point events is very small, thus making it impractical to conduct an experiment to look for the end point. The measurement of surrogate markers provides a way to test the effectiveness of a treatment for a fatal disease without having to wait for a statistically significant number of deaths to occur. the FDA will often accept evidence from clinical trials that show a benefit to surrogate markers instead of to end points.

A commonly used example is cholesterol. A clinical trial may show that a particular drug is effective in reducing cholesterol. A high cholesterol is associated with death from heart disease, so it is believed that a treatment that is effective in reducing cholesterol must also be effective in reducing death from heart disease. "Death from heart disease" is the endpoint of interest, but "cholesterol" is the surrogate marker.

Examples of other surrogate markers include:

  • fragmented blood cells are a surrogate marker for organ failure or stroke in

TTP;

  • the S-phase duration, may be used as a surrogate marker for breast cancer occurrence;
  • CD4 count is a surrogate marker for death from HIV infection.

Criticism

There have been a number of instances when studies using surrogate markers have been used to show benefit from a particular treatment, but later, a repeat study looking at endpoints has not shown a benefit, or even a harm.[2]

References

  1. ^ Cohn JN (2004). "Introduction to Surrogate Markers". Circulation 109: IV20–1. PMID 15226247. Retrieved on 2007-01-10.
  2. ^ Psaty BM, Weiss NS, Furberg CD, et al. (1999). "Surrogate end points, health outcomes, and the drug approval process for the treatment of risk factors for cardiovascular disease". JAMA 282: 786–790.

'"/>


(Date:5/26/2016)... ... May 26, 2016 , ... Catalent Pharma Solutions, ... biologics, consumer health and global clinical supply services, today announced two key appointments ... company’s continued investment and strategic growth plans in the Asia Pacific region. , ...
(Date:5/26/2016)... ... May 26, 2016 , ... Leadership of Life ... announced the organization has earned its ISO 13485 certification, indicating the company’s quality ... all rules and policies associated with ISO quality standard 13485. , BSI ...
(Date:5/26/2016)... York, NY (PRWEB) , ... May 26, 2016 ... ... researcher, founder of Mehling Orthopedics and chief medical officer of Blue Horizon International ... Disease and Regeneration. The conference was held during May 5-6, 2016 in Chicago, ...
(Date:5/26/2016)... ... May 26, 2016 , ... OncLive® , ... National Cancer Institute-designated University of Virginia (UVA) Cancer Center to its ... editorial and marketing teams will publicize and promote public awareness of UVA Cancer ...
(Date:5/26/2016)... ... May 26, 2016 , ... Metcalf & Associates’ ... 20 years of experience in leading technology and human resources operations for health ... teaching, Morrow-Fox will be featured on Metcalf’s VoiceAmerica radio show , Innovative ...
Breaking Medicine News(10 mins):
Other medicine definition